Associations - FLT3 mutation

BIOMARKER:

FLT3 mutation

Entrez ID:

2322

Related biomarkers:

‹

›

FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria Hypomethylating agent + venetoclax Sensitive : C2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Sensitive: C3 – Early Trials venetoclax + sorafenib Sensitive : C3
FLT3 mutation FLT3 mutation	Non Small Cell Lung Cancer NSCLC	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	quizartinib + RAIN-32 Sensitive: D – Preclinical quizartinib + RAIN-32 Sensitive : D
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	MEK inhibitor + FLT3 inhibitor Sensitive: D – Preclinical MEK inhibitor + FLT3 inhibitor Sensitive : D
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	sorafenib + LY3009120 Sensitive: D – Preclinical sorafenib + LY3009120 Sensitive : D
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	PF-02545920 Sensitive: D – Preclinical PF-02545920 Sensitive : D
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	5-fluorouracil Sensitive: D – Preclinical 5-fluorouracil Sensitive : D
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	quizartinib + IACS-010759 Sensitive: D – Preclinical quizartinib + IACS-010759 Sensitive : D
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	AG-1296 Sensitive: D – Preclinical AG-1296 Sensitive : D
FLT3 mutation FLT3 mutation	Chronic Myeloid Leukemia CML	sunitinib Sensitive: D – Preclinical sunitinib Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES